Drugs / Dociparstat
Dociparstat
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02995655 | Apr 2017 → Sep 2018 | acute myeloid leukemia, myelodysplastic syndrome | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02056782 | Dec 2013 → Feb 2015 | acute myeloid leukemia | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02873338 | Aug 2016 → Jun 2019 | acute myeloid leukemia | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01461915 | Nov 2011 → Dec 2012 | malignant pancreatic neoplasm | Jazz Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04389840 | Jul 2020 → May 2021 | COVID-19, acute lung injury | Jazz Pharmaceuticals | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04571645 | Apr 2021 → May 2022 | acute myeloid leukemia | Jazz Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dociparstat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01461915 ↗ |
| Known as | CX-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02995655 ↗ |
| Known as | dociparstat sodium | “This was a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the safety and efficacy of dociparstat sodium in adult patients with acute lung injury (ALI)...” NCT04389840 ↗ |
| Action | Inhibit | “Autophagy appears to be largely driven by the binding of high mobility group box-1 protein (HMGB1) to the receptor for advanced glycation end-products (RAGE), which is strongly...” NCT01461915 ↗ |
| Modality | Other / unclassified | “Dociparstat is a glycosaminoglycan derived from porcine heparin.” NCT04389840 ↗ |
| Route | Intravenous | “dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration.” NCT01461915 ↗ |